Binimetinib, encorafenib and cetuximab (BEACON Trial) combination therapy for patients with BRAF V600E-mutant metastatic colorectal cancer.

Overview of attention for article published in Drugs of Today = Medicamentos de actualidad, January 2019

Altmetric Badge

About this Attention Score

Above-average Attention Score compared to outputs of the same age (63rd percentile)
Above-average Attention Score compared to outputs of the same age and source (60th percentile)

Mentioned by

policy: 1 policy source

twitter: 2 X users

Readers on

mendeley: 24 Mendeley

So far, Altmetric has seen 1 policy document that references this research output.

encorafenib - Clinical and Pharmacoeconomic combined Report

Cited by Canadian Agency for Drugs and Technologies in Health (CADTH) on 26 Jul 2021

CADTH is an independent, not-for-profit organization responsible for providing health care decision-makers with objective evidence to help make informed decisions about the optimal use of health technologies.

This page shows the most recent policy documents that mention this research output. Click here to find out how to access more activity.